Skip to content

The effect of high-dose immunoglobulin pulse therapy on the prognosis of hepatitis B virus associated acute-on-chronic liver failure

The effect of high-dose immunoglobulin pulse therapy on the prognosis of hepatitis B virus associated acute-on-chronic liver failure: a multi-center retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106857
Enrollment
Unknown
Registered
2025-07-31
Start date
2025-07-31
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B virus related acute-on-chronic liver failure

Interventions

High-dose intravenous immunoglobulin group (IVIg Group):NA
Standard medical treatment Group (SMT Group):NA

Sponsors

Second Affiliated Hospital of Shantou University Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.We adopt the diagnostic criteria of acute on chronic liver failure (2009 version) issued by the Asian Pacific Association for the study of the liver (APASL), which is more suitable for patients in the Asia Pacific region. The criteria include acute injury of liver function occur on the basis of known or unknown chronic liver diseases, which have jaundice [diagnostic index: total bilirubin (TBIL) = 85 µ mol/l or 5 mg/dl, which must be reached]; and have abnormal coagulation function [diagnostic index: prothrombin time activity (PTA) 5 × 10E2 copies/ml; 4.Cases' ages ranged from 18 to 65 completed years.

Exclusion criteria

Exclusion criteria: 1.Cases with alcoholic liver disease, drug-induced liver disease and cholestatic liver disease will be excluded; 2.Cases with decompensated cirrhosis will be excluded; 3.Cases with autoimmune liver disease or other autoimmune diseases will be excluded; 4.Cases with coinfection of hepatitis A, C, D, E virus or other liver related virus infections will be excluded; 5.Cases with diabetes, pancreatitis or other diseases that seriously affect metabolism will be excluded; 6.Cases with tuberculosis, epilepsy or other diseases which need medicine may causing relatively great liver injury will be excluded; 7.Cases received immunoglobulin, glucocorticoid or anticoagulant drugs within 4 weeks before admission will be excluded; 8.Cases with malignant tumor, cardiorespiratory, renal failure or severe infection of other organs will be excluded;

Design outcomes

Primary

MeasureTime frame
Survival rate;

Secondary

MeasureTime frame
The score of model for end-stage liver disease (MELD).;

Countries

China

Contacts

Public ContactWeidong Liu

Second Affiliated Hospital of Shantou University Medical College

weidongliu206@163.com+86 189 2964 1506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026